Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06168253 · ClinicalTrials.gov registry record · NA
Text Message Safety Behavior Fading for Social Anxiety
A NA study, sponsored by Florida State University.
- Completed
- Registry status
- NA
- Development phase
- 201
- Enrollment target
NCT06168253: Completed NA study, sponsored by Florida State University.
NCT06168253 is a NA study that has completed, run by Florida State University. The registered enrollment target is 201 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06168253, a NA study, has completed, sponsored by Florida State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 201 participants
- Enrollment target
Study Summary
The current study aims to explore the efficacy of a text message based Safety Behavior Fading Intervention compared to an active control intervention.
Primary Outcome
Self-report scale that measures Social anxiety symptoms. Scores range from 0 to 68 with higher scores indicating higher levels of social anxiety symptoms.
Interventions
- BEHAVIORAL Unhealthy Behavior Fading
- BEHAVIORAL Safety Behavior Fading for Social Anxiety
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2024-09-01 |
| Phase | NA |
What the finished NCT06168253 record still lists
NCT06168253 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Unhealthy Behavior Fading is the first listed.
NCT06168253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06168253 about?
NCT06168253 is a clinical study titled "Text Message Safety Behavior Fading for Social Anxiety". The current study aims to explore the efficacy of a text message based Safety Behavior Fading Intervention compared to an active control intervention.
What is the current status of trial NCT06168253?
This trial is currently completed. It is a NA study. The enrollment target is 201 participants. The study started on 2024-01-01. Estimated completion is 2024-09-01.
What interventions are being tested in trial NCT06168253?
The interventions under investigation include: Unhealthy Behavior Fading (BEHAVIORAL), Safety Behavior Fading for Social Anxiety (BEHAVIORAL).
Who is sponsoring clinical trial NCT06168253?
This trial is sponsored by Florida State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06168253's enrollment target sits among peer trials
201 506th of 2000 higher than 1,495 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI